Neupulse Nominated for Outstanding Achievement at 2025 Medilink Business Awards

We’re proud to announce that Neurotheraputics Ltd, the company behind Neupulse, has been officially named a finalist for the Outstanding Achievement Award at the Medilink Midlands Business Awards 2025, recognising our work in advancing wearable technology for neurological health.

The awards, which celebrate innovation and excellence across the medtech and life sciences sectors, revealed this year’s finalists during a networking event held on 13^th March in partnership with the West Midlands Health Tech Accelerator (WMHTIA). The event brought together businesses, innovators and thought leaders from across the region to recognise those making meaningful contributions to patient care and medical advancement.

A Milestone Moment for Neupulse

Our nomination in the Outstanding Achievement category is a significant milestone for the entire Neupulse team. It reflects the dedication, vision and collaboration that have gone into the development of our flagship wearable device — designed to reduce involuntary movements in individuals with Tourette Syndrome.

Since launching our research and development efforts, Neupulse has remained focused on creating accessible, non-invasive and user-friendly technology that empowers users to regain control over their movement and daily routines. This recognition by Medilink Midlands serves as validation of that mission and highlights the potential impact our work could have on people’s lives.

Celebrating Innovation in Health Tech

The Medilink Midlands Business Awards are among the most prestigious accolades in the UK medtech landscape. Organised annually, the awards recognise excellence across a wide range of categories — from innovation and exporting, to sustainability and outstanding service delivery. The awards also shine a light on both start-ups and established organisations that are making meaningful strides in improving patient outcomes and transforming the healthcare system.

Melanie Davidson, Chief Executive Officer at Medilink Midlands, commented on the calibre of this year’s nominees:

“Congratulations to the finalists of the Medilink Midlands Business Awards 2025. Each year, we are inspired by the outstanding calibre of applications and this year is no exception. It is fantastic to celebrate the exceptional work taking place to drive innovation and improve patient outcomes. On behalf of the Medilink Midlands team, I wish all the finalists the best of luck and look forward to celebrating with them at the awards ceremony in May.”

We are honoured to be among a list of inspiring organisations that are pushing the boundaries of health tech innovation, from academic research hubs to cutting-edge manufacturers.

Where Innovation Meets Impact

Neupulse’s nomination is particularly exciting as we prepare for a pivotal stage in our journey — the launch of our first product, planned for early 2026. This wearable wrist device is designed to provide real-time neuromodulation to help reduce tics and involuntary movements in individuals with Tourette Syndrome, backed by ongoing research and clinical studies.

Our technology combines medical insight, wearable comfort and real-world usability to deliver an effective non-pharmaceutical option for those affected by neurological conditions. The nomination acknowledges not only the technological advancement behind the device but also the potential social impact — empowering individuals to live with greater freedom, confidence and control. 

Looking Ahead to the Awards Ceremony

Winners will be announced during the Medilink Midlands Business Awards Ceremony on 15 May 2025, held at the Grand Station in Wolverhampton. The event, hosted by TV doctor and adventurer Dr Will Duffin, promises an evening of celebration, networking and entertainment with the region’s top innovators in life sciences and medtech.

The Neupulse team will be in attendance, representing not just our own company, but also the wider community of researchers, engineers and participants who have contributed to our progress.

A Shared Success

This recognition would not be possible without the collaborative support of our trial participants and the incredible individuals who have shared their stories with us throughout the development process. It’s through their feedback and encouragement that we continue to refine and evolve our technology.

We’re also incredibly grateful to our growing community of early supporters and prospective users who have joined us on this journey. Whether you’ve signed up to receive updates, taken part in clinical research or simply followed our story — this nomination is a shared success and we thank you for being a part of it.

Join Us on the Journey

We’ll be sharing updates as we approach the awards ceremony in May — and even more exciting milestones as we move closer to launch in 2026. If you’d like to stay connected, learn more about our research, or express interest in future clinical trials, we invite you to join our mailing list or get involved today.

To learn more about the Medilink Midlands Business Awards and view the full list of 2025 finalists, visit medilinkmidlands.com.